Jessica Cardenas
Concepts (234)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Venous Thromboembolism | 11 | 2024 | 332 | 4.680 |
Why?
| | Wounds and Injuries | 29 | 2026 | 959 | 4.560 |
Why?
| | Thrombosis | 12 | 2026 | 398 | 3.930 |
Why?
| | Hemostasis | 15 | 2026 | 100 | 3.860 |
Why?
| | Shock, Hemorrhagic | 10 | 2026 | 195 | 3.490 |
Why?
| | Blood Coagulation Disorders | 12 | 2025 | 190 | 3.160 |
Why?
| | Thrombin | 16 | 2026 | 175 | 2.190 |
Why?
| | Endothelial Cells | 9 | 2026 | 876 | 2.180 |
Why?
| | Hemorrhage | 9 | 2026 | 825 | 1.660 |
Why?
| | Fibrinolysis | 8 | 2026 | 162 | 1.630 |
Why?
| | Thrombophilia | 4 | 2022 | 89 | 1.480 |
Why?
| | Thrombelastography | 18 | 2026 | 182 | 1.440 |
Why?
| | Enoxaparin | 3 | 2022 | 68 | 1.420 |
Why?
| | Endothelium, Vascular | 8 | 2026 | 952 | 1.420 |
Why?
| | Blood Platelets | 8 | 2026 | 382 | 1.350 |
Why?
| | Blood Transfusion | 9 | 2026 | 394 | 1.350 |
Why?
| | Antithrombins | 4 | 2025 | 71 | 1.340 |
Why?
| | Syndecan-1 | 6 | 2023 | 42 | 1.230 |
Why?
| | Blood Coagulation | 12 | 2025 | 267 | 1.130 |
Why?
| | Blood Component Transfusion | 7 | 2026 | 99 | 1.050 |
Why?
| | Fibrinogen | 6 | 2026 | 182 | 0.970 |
Why?
| | Antithrombin III | 3 | 2022 | 18 | 0.960 |
Why?
| | Plasma | 3 | 2026 | 222 | 0.950 |
Why?
| | Extracellular Vesicles | 3 | 2026 | 176 | 0.930 |
Why?
| | von Willebrand Factor | 2 | 2025 | 84 | 0.800 |
Why?
| | Cadherins | 2 | 2023 | 202 | 0.720 |
Why?
| | Platelet Transfusion | 2 | 2019 | 76 | 0.660 |
Why?
| | Shock | 2 | 2021 | 101 | 0.650 |
Why?
| | alpha-2-Antiplasmin | 3 | 2026 | 4 | 0.630 |
Why?
| | Inflammation | 7 | 2026 | 2919 | 0.620 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2024 | 449 | 0.610 |
Why?
| | Rats, Sprague-Dawley | 7 | 2026 | 2537 | 0.590 |
Why?
| | Plasminogen Activator Inhibitor 1 | 3 | 2019 | 83 | 0.580 |
Why?
| | Brain Injuries, Traumatic | 6 | 2025 | 466 | 0.570 |
Why?
| | Humans | 69 | 2026 | 146342 | 0.560 |
Why?
| | Periodicals as Topic | 1 | 2021 | 214 | 0.560 |
Why?
| | Anticoagulants | 5 | 2023 | 746 | 0.510 |
Why?
| | Cell-Derived Microparticles | 2 | 2015 | 73 | 0.500 |
Why?
| | Prospective Studies | 17 | 2025 | 8123 | 0.480 |
Why?
| | Injury Severity Score | 10 | 2025 | 572 | 0.480 |
Why?
| | Fibrinolysin | 2 | 2026 | 20 | 0.470 |
Why?
| | Rats | 6 | 2026 | 5586 | 0.460 |
Why?
| | Male | 42 | 2026 | 73396 | 0.460 |
Why?
| | Capillary Permeability | 3 | 2023 | 133 | 0.440 |
Why?
| | Tissue Plasminogen Activator | 3 | 2026 | 245 | 0.440 |
Why?
| | Endothelial Progenitor Cells | 1 | 2015 | 19 | 0.430 |
Why?
| | Adult | 33 | 2026 | 41087 | 0.410 |
Why?
| | Middle Aged | 31 | 2026 | 36619 | 0.390 |
Why?
| | Hemostatics | 2 | 2023 | 66 | 0.350 |
Why?
| | Inflammation Mediators | 2 | 2025 | 508 | 0.340 |
Why?
| | Obesity, Morbid | 1 | 2015 | 287 | 0.320 |
Why?
| | Animals | 14 | 2026 | 38107 | 0.320 |
Why?
| | Thrombomodulin | 4 | 2025 | 15 | 0.320 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2015 | 385 | 0.300 |
Why?
| | Resuscitation | 5 | 2026 | 314 | 0.290 |
Why?
| | Glycocalyx | 3 | 2019 | 30 | 0.280 |
Why?
| | Female | 34 | 2026 | 79499 | 0.270 |
Why?
| | Blood Coagulation Tests | 5 | 2025 | 72 | 0.260 |
Why?
| | Fibrin | 3 | 2023 | 84 | 0.250 |
Why?
| | Risk Factors | 8 | 2025 | 10921 | 0.250 |
Why?
| | Postoperative Complications | 2 | 2023 | 3034 | 0.250 |
Why?
| | Factor VIII | 2 | 2026 | 107 | 0.250 |
Why?
| | Radiobiology | 1 | 2026 | 7 | 0.240 |
Why?
| | Blood Preservation | 2 | 2021 | 346 | 0.240 |
Why?
| | Cohort Studies | 5 | 2022 | 6077 | 0.240 |
Why?
| | Endothelium | 2 | 2023 | 119 | 0.230 |
Why?
| | Radiation Oncology | 1 | 2026 | 83 | 0.220 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2023 | 92 | 0.220 |
Why?
| | Interleukin-8 | 2 | 2023 | 268 | 0.220 |
Why?
| | Interleukin-6 | 3 | 2025 | 784 | 0.210 |
Why?
| | Retrospective Studies | 7 | 2024 | 17438 | 0.210 |
Why?
| | Oxidative Stress | 2 | 2025 | 1369 | 0.210 |
Why?
| | ABO Blood-Group System | 1 | 2025 | 56 | 0.210 |
Why?
| | Blood Donors | 1 | 2026 | 145 | 0.210 |
Why?
| | Platelet Function Tests | 6 | 2022 | 37 | 0.200 |
Why?
| | Mice, Inbred C57BL | 3 | 2026 | 6034 | 0.200 |
Why?
| | Coagulants | 1 | 2023 | 20 | 0.200 |
Why?
| | Endothelial Protein C Receptor | 1 | 2023 | 6 | 0.200 |
Why?
| | Sulfates | 1 | 2023 | 45 | 0.190 |
Why?
| | Platelet Aggregation | 5 | 2022 | 99 | 0.180 |
Why?
| | Chemokines | 1 | 2023 | 217 | 0.180 |
Why?
| | Chemoprevention | 1 | 2023 | 91 | 0.180 |
Why?
| | Biomarkers | 10 | 2026 | 4340 | 0.180 |
Why?
| | Sarcoidosis, Pulmonary | 1 | 2023 | 100 | 0.170 |
Why?
| | Venous Thrombosis | 1 | 2023 | 199 | 0.170 |
Why?
| | Lung Injury | 1 | 2025 | 263 | 0.170 |
Why?
| | Pulmonary Embolism | 1 | 2023 | 246 | 0.160 |
Why?
| | Infusion Pumps | 1 | 2020 | 33 | 0.160 |
Why?
| | Sarcoidosis | 1 | 2023 | 164 | 0.160 |
Why?
| | Endovascular Procedures | 1 | 2025 | 390 | 0.150 |
Why?
| | Mice | 5 | 2026 | 18297 | 0.150 |
Why?
| | Interferon-gamma | 1 | 2023 | 781 | 0.150 |
Why?
| | Publishing | 1 | 2021 | 117 | 0.150 |
Why?
| | Time Factors | 5 | 2025 | 7109 | 0.150 |
Why?
| | Catecholamines | 2 | 2017 | 88 | 0.150 |
Why?
| | Neutrophil Infiltration | 1 | 2020 | 107 | 0.150 |
Why?
| | Cells, Cultured | 2 | 2025 | 4118 | 0.150 |
Why?
| | Liver | 2 | 2026 | 1864 | 0.150 |
Why?
| | Disease Models, Animal | 5 | 2026 | 4580 | 0.150 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2023 | 297 | 0.140 |
Why?
| | Multiple Trauma | 1 | 2020 | 118 | 0.140 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2022 | 499 | 0.140 |
Why?
| | Peripheral Arterial Disease | 1 | 2025 | 507 | 0.140 |
Why?
| | Mitochondria | 1 | 2025 | 997 | 0.140 |
Why?
| | Cytokines | 1 | 2025 | 2081 | 0.130 |
Why?
| | Serum Albumin | 1 | 2018 | 147 | 0.130 |
Why?
| | E-Selectin | 1 | 2017 | 61 | 0.120 |
Why?
| | Incidence | 1 | 2024 | 2936 | 0.120 |
Why?
| | Blood Coagulation Factors | 3 | 2026 | 71 | 0.120 |
Why?
| | Electric Injuries | 1 | 2016 | 2 | 0.120 |
Why?
| | Intracranial Hemorrhages | 1 | 2017 | 106 | 0.120 |
Why?
| | Aged | 8 | 2026 | 26432 | 0.120 |
Why?
| | Adrenal Glands | 1 | 2017 | 77 | 0.120 |
Why?
| | Burns, Electric | 1 | 2016 | 25 | 0.120 |
Why?
| | Disease-Free Survival | 1 | 2018 | 778 | 0.120 |
Why?
| | RNA | 1 | 2023 | 926 | 0.120 |
Why?
| | Transcriptome | 1 | 2023 | 1068 | 0.120 |
Why?
| | Predictive Value of Tests | 4 | 2026 | 2113 | 0.120 |
Why?
| | Sympathetic Nervous System | 1 | 2017 | 177 | 0.110 |
Why?
| | Energy Drinks | 1 | 2015 | 3 | 0.110 |
Why?
| | Platelet Count | 3 | 2021 | 95 | 0.110 |
Why?
| | Dietary Supplements | 1 | 2020 | 587 | 0.110 |
Why?
| | Apoptosis | 2 | 2025 | 2439 | 0.110 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2020 | 1224 | 0.110 |
Why?
| | Cysteine-Rich Protein 61 | 1 | 2014 | 6 | 0.110 |
Why?
| | Fluid Therapy | 1 | 2016 | 154 | 0.110 |
Why?
| | Vascular Diseases | 1 | 2017 | 252 | 0.100 |
Why?
| | Lung | 2 | 2025 | 4122 | 0.100 |
Why?
| | Blood Specimen Collection | 1 | 2014 | 37 | 0.100 |
Why?
| | Pancreatic Neoplasms | 1 | 2023 | 944 | 0.100 |
Why?
| | Cell Line | 1 | 2020 | 2814 | 0.100 |
Why?
| | Protein C | 1 | 2014 | 54 | 0.100 |
Why?
| | Emergency Medical Services | 1 | 2021 | 680 | 0.100 |
Why?
| | Wounds, Nonpenetrating | 1 | 2017 | 305 | 0.100 |
Why?
| | Hemostatic Techniques | 1 | 2014 | 50 | 0.100 |
Why?
| | Survival Rate | 1 | 2018 | 2092 | 0.100 |
Why?
| | Texas | 1 | 2014 | 280 | 0.100 |
Why?
| | Case-Control Studies | 3 | 2016 | 3647 | 0.090 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2014 | 320 | 0.090 |
Why?
| | Homeostasis | 1 | 2016 | 646 | 0.090 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2018 | 846 | 0.080 |
Why?
| | Oxidation-Reduction | 1 | 2014 | 1075 | 0.080 |
Why?
| | ROC Curve | 2 | 2026 | 617 | 0.080 |
Why?
| | Neoplasms | 1 | 2026 | 2954 | 0.080 |
Why?
| | Severity of Illness Index | 2 | 2015 | 2921 | 0.070 |
Why?
| | Prognosis | 4 | 2019 | 4351 | 0.070 |
Why?
| | Young Adult | 7 | 2019 | 14330 | 0.070 |
Why?
| | Trauma Severity Indices | 2 | 2018 | 115 | 0.060 |
Why?
| | Cell Proliferation | 1 | 2014 | 2502 | 0.060 |
Why?
| | Color | 1 | 2026 | 80 | 0.060 |
Why?
| | Cell Adhesion Molecules | 1 | 2025 | 180 | 0.050 |
Why?
| | Trauma Centers | 2 | 2017 | 441 | 0.050 |
Why?
| | Calcium-Binding Proteins | 1 | 2025 | 221 | 0.050 |
Why?
| | Cell Adhesion | 1 | 2025 | 447 | 0.050 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2023 | 37 | 0.050 |
Why?
| | Longitudinal Studies | 2 | 2026 | 3017 | 0.050 |
Why?
| | Aged, 80 and over | 3 | 2025 | 8391 | 0.050 |
Why?
| | Pilot Projects | 2 | 2022 | 1888 | 0.050 |
Why?
| | Multivariate Analysis | 2 | 2017 | 1543 | 0.050 |
Why?
| | Medical Futility | 1 | 2023 | 32 | 0.050 |
Why?
| | Biology | 1 | 2023 | 90 | 0.050 |
Why?
| | Reference Standards | 1 | 2023 | 176 | 0.050 |
Why?
| | Heparin | 1 | 2023 | 247 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2025 | 610 | 0.040 |
Why?
| | Vital Capacity | 1 | 2023 | 293 | 0.040 |
Why?
| | Cell Separation | 1 | 2023 | 300 | 0.040 |
Why?
| | Immunomodulation | 1 | 2023 | 98 | 0.040 |
Why?
| | Breast Neoplasms | 1 | 2014 | 2418 | 0.040 |
Why?
| | Immunization, Passive | 1 | 2021 | 90 | 0.040 |
Why?
| | Logistic Models | 2 | 2017 | 2126 | 0.040 |
Why?
| | Genomics | 1 | 2026 | 853 | 0.040 |
Why?
| | Leukocyte Reduction Procedures | 1 | 2020 | 29 | 0.040 |
Why?
| | B7-H1 Antigen | 1 | 2023 | 245 | 0.040 |
Why?
| | Metabolomics | 1 | 2026 | 738 | 0.040 |
Why?
| | Chemokine CCL2 | 1 | 2020 | 112 | 0.040 |
Why?
| | Intensive Care Units | 1 | 2026 | 925 | 0.040 |
Why?
| | Flow Cytometry | 1 | 2023 | 1163 | 0.040 |
Why?
| | Cold Temperature | 1 | 2020 | 208 | 0.040 |
Why?
| | Proteomics | 1 | 2026 | 1203 | 0.040 |
Why?
| | In Vitro Techniques | 1 | 2020 | 1041 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2023 | 747 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2025 | 3125 | 0.030 |
Why?
| | Urokinase-Type Plasminogen Activator | 1 | 2017 | 25 | 0.030 |
Why?
| | Multicenter Studies as Topic | 1 | 2019 | 417 | 0.030 |
Why?
| | Edema | 1 | 2018 | 131 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2025 | 11821 | 0.030 |
Why?
| | Neutrophils | 1 | 2023 | 1133 | 0.030 |
Why?
| | Platelet Adhesiveness | 1 | 2016 | 14 | 0.030 |
Why?
| | Antifibrinolytic Agents | 1 | 2017 | 68 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2020 | 561 | 0.030 |
Why?
| | Epinephrine | 1 | 2017 | 160 | 0.030 |
Why?
| | Norepinephrine | 1 | 2017 | 201 | 0.030 |
Why?
| | Kaolin | 1 | 2015 | 7 | 0.030 |
Why?
| | Risk Assessment | 1 | 2025 | 3712 | 0.030 |
Why?
| | Methionine | 1 | 2016 | 160 | 0.030 |
Why?
| | Arachidonic Acid | 1 | 2015 | 101 | 0.030 |
Why?
| | Fibrin Clot Lysis Time | 1 | 2014 | 10 | 0.030 |
Why?
| | Linear Models | 1 | 2017 | 857 | 0.030 |
Why?
| | Healthy Volunteers | 1 | 2015 | 218 | 0.030 |
Why?
| | Punctures | 1 | 2014 | 40 | 0.030 |
Why?
| | Partial Thromboplastin Time | 1 | 2014 | 53 | 0.030 |
Why?
| | Random Allocation | 1 | 2015 | 366 | 0.030 |
Why?
| | Thromboplastin | 1 | 2014 | 67 | 0.030 |
Why?
| | 3T3 Cells | 1 | 2014 | 152 | 0.030 |
Why?
| | Forkhead Box Protein O1 | 1 | 2014 | 36 | 0.030 |
Why?
| | MCF-7 Cells | 1 | 2014 | 133 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2019 | 1064 | 0.030 |
Why?
| | Survival Analysis | 1 | 2017 | 1378 | 0.020 |
Why?
| | Solubility | 1 | 2014 | 240 | 0.020 |
Why?
| | Early Diagnosis | 1 | 2014 | 251 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2017 | 1331 | 0.020 |
Why?
| | Forkhead Transcription Factors | 1 | 2014 | 209 | 0.020 |
Why?
| | Femoral Artery | 1 | 2014 | 183 | 0.020 |
Why?
| | Forecasting | 1 | 2014 | 388 | 0.020 |
Why?
| | Reference Values | 1 | 2014 | 796 | 0.020 |
Why?
| | Adolescent | 3 | 2017 | 22557 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1763 | 0.020 |
Why?
| | MAP Kinase Signaling System | 1 | 2014 | 307 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2017 | 1998 | 0.020 |
Why?
| | Hospitalization | 1 | 2023 | 2475 | 0.020 |
Why?
| | Hospital Mortality | 1 | 2017 | 1051 | 0.020 |
Why?
| | Burns | 1 | 2016 | 365 | 0.020 |
Why?
| | Cardiac Catheterization | 1 | 2014 | 571 | 0.020 |
Why?
| | Cell Movement | 1 | 2014 | 951 | 0.020 |
Why?
| | Pregnancy | 1 | 2022 | 7230 | 0.020 |
Why?
| | Models, Biological | 1 | 2016 | 1761 | 0.020 |
Why?
| | Prevalence | 1 | 2015 | 2861 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2014 | 3416 | 0.010 |
Why?
| | Phenotype | 1 | 2014 | 3206 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2015 | 6460 | 0.010 |
Why?
| | Infant | 1 | 2015 | 10114 | 0.010 |
Why?
| | Child, Preschool | 1 | 2015 | 11913 | 0.010 |
Why?
| | United States | 1 | 2014 | 16136 | 0.010 |
Why?
| | Child | 1 | 2015 | 22693 | 0.010 |
Why?
|
|
Cardenas's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|